{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-22-000102","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.131404+00:00","generated_at":"2026-06-21T07:38:55.995663+00:00","sec_items":["2.05","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Instil Bio discontinues ITIL-168, cuts 60% of U.S. workforce, COO departs","bullets":["Discontinuing ITIL-168 (unmodified TIL) programs; prioritizing CoStAR-TIL platform (ITIL-306) in Phase 1 for NSCLC, ovarian, RCC.","U.S. workforce reduced by ~60%; restructuring expected substantially complete in February 2023.","Estimated aggregate restructuring costs up to $20 million; COO Timothy Moore departing Dec 8, 2022, consulting 3 months.","Initial ITIL-306 Phase 1 data expected in 2023; first patient dosed in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-22-000102","json":"https://secwatch.observer/filing/0001789769-22-000102.json","markdown":"https://secwatch.observer/filing/0001789769-22-000102.md","text":"https://secwatch.observer/filing/0001789769-22-000102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976922000102/0001789769-22-000102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976922000102/til-20221202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:38:55.995663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a3b6ee0835","claim":"Timothy Moore departed as Chief Operating Officer at Instil Bio, Inc..","evidence_excerpt":"Timothy Moore, the Company’s Chief Operating Officer, will separate from the Company, effective December 8, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976922000102/0001789769-22-000102-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"will separate"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"0e4e9e774d3733f647f5d45b75255011f1b1a47b","claim":"Instil Bio, Inc. announced a restructuring with charges of up to $20 million affecting ITIL-168 development program and U.S. workforce (approximately 60%).","evidence_excerpt":"As part of the Plan, the Company’s ITIL-168 development program will be discontinued. In addition, as part of the Plan, the Company will reduce its US workforce by approximately 60%. This workforce reduction is expected to be substantially completed in February 2023. In connection with the Plan, the Company estimates that it will incur aggregate restructuring costs of up to $20 million.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976922000102/0001789769-22-000102-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"up to $20 million"},{"label":"Affected area","value":"ITIL-168 development program and U.S. workforce"},{"label":"Headcount","value":"approximately 60%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}